AOP Health has explored a new method for processing credit

WIEN, October 1, 2024–(BUSINESS WIRE)–AOP Orphan Pharmaceuticals GmbH (AOP Health) together with Leukos Biotech has a number of Meilenstein erreicht. The first patient is working in the clinical version of SERONCO-1 of phase I, studied in a substance with a new and unique working mechanism (first class). The drug can be used in patients with severe tumors and lymphomas. As AOP Health develops, it is possible that credit institutions will turn to the machine, which will enable new treatment methods for patients.

Focus on a lost soul

The new connection, AOP208, activates and blocks a protein in the upper layer of the Krebsstammzel, the serotonin receptor 1B, which possibly stimulates the Erkrankung-dart. The Zusammenstellung has been stated orally and is said to have been based on research at the Josep-Carreras Leukemia Research Institute by Leukos Biotech.

Ruth Risueño, Chief Scientific Officer at Leukos Biotech, explains: “A new path to the treatment of credit strains can be found, which has a responsible effect on the treatment and control of the tumors. There is no evidence that the serotonin receptor is separated from the process that is. There are no specific molecular components for the blocking of the receptors, hereditary and a new one. Nun can extend to clinical treatment and can have our concern for the next study .”

AOP Health discontinued a Lizenz which has more rights to the Entwicklung for AOP208, such as the global rights to the market, including for the US, Europe, Korea and Taiwan or the People’s Republic of China.

First patient was discussed with AOP208

SERONCO-1, a First-in-Human version with AOP208, has started, patients with tumors (einschließliche Krebs with metastases) and lymphomas are being resolved. The first patient welfare was discussed. The translation comes from Dr. Irene Braña in Zusammenarbeit with Leukos Biotech in Vall d’Hebron Institute of Oncology (VHIO) through time. The Spanish Ministry of Science and Innovation has launched a public-private partnership program (CPP2021-008715).

The treatment of the first patients with AOP208 in the future is a more severe punishment, the certainty and effectiveness of the drugs you have to test. SERONCO-1 would not work, causing AOP208 to become infected by the tumors.

Research into new methods for Krebstherapie is urgently needed, so Christoph Klade, Chief Scientific Officer at AOP Health: “AOP208 is a result of a rezeptor of Krebsstammzellen, which means that both of the Krebstherapie have little effect. So go with AOP208 in oncology and a very interesting drug. It may be that art of leukemia and a celebration of tumors with breast and lung growth play an exciting role.”

Read more